Published in J Clin Hypertens (Greenwich) on October 01, 2007
Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis. Hypertension (2008) 1.67
Novel therapeutic targets for hypertension. Nat Rev Cardiol (2010) 1.13
Emerging therapies for chronic kidney disease: what is their role? Nat Rev Nephrol (2009) 1.03
Antihypertensive agents in hemodialysis patients: a current perspective. Semin Dial (2010) 1.02
Endothelin. Pharmacol Rev (2016) 0.95
Resistant hypertension workup and approach to treatment. Int J Hypertens (2010) 0.94
Endothelin-1, aging and hypertension. Curr Opin Cardiol (2008) 0.88
A Network Meta-Analysis of Clinical Management Strategies for Treatment-Resistant Hypertension: Making Optimal Use of the Evidence. J Gen Intern Med (2017) 0.81
Endothelin receptor polymorphisms in the cardiovascular system: potential implications for therapy and screening. Heart Fail Rev (2014) 0.77
Clinical approach in treatment of resistant hypertension. Integr Blood Press Control (2009) 0.75
Association of oral endothelin receptor antagonists with risks of cardiovascular events and mortality: meta-analysis of randomized controlled trials. Eur J Clin Pharmacol (2016) 0.75
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 63.78
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
A controlled trial of renal denervation for resistant hypertension. N Engl J Med (2014) 14.22
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med (2008) 11.61
Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med (2006) 9.40
Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med (2013) 8.74
Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med (2010) 8.48
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med (2013) 7.54
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet (2012) 6.69
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med (2014) 5.93
Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA (2010) 5.06
Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med (2003) 4.72
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation (2006) 4.61
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med (2015) 4.50
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care (2007) 4.30
Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med (2003) 4.08
Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension (2006) 3.89
Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA (2003) 3.71
Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med (2008) 3.71
HIV prevention among sex workers in India. J Acquir Immune Defic Syndr (2004) 3.38
Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich) (2013) 2.94
Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med (2014) 2.90
Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens (2014) 2.82
First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol (2005) 2.82
Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem (2011) 2.82
Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care (2011) 2.75
Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis (2003) 2.68
Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol (2008) 2.63
Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol (2006) 2.58
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol (2007) 2.56
Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol (2010) 2.43
Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol (2011) 2.40
Expanding the definition and classification of hypertension. J Clin Hypertens (Greenwich) (2005) 2.35
The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab (2008) 2.34
Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens (2014) 2.28
Awareness of kidney disease and relationship to end-stage renal disease and mortality. Am J Med (2012) 2.24
Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis (2010) 2.18
Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med (2007) 2.14
Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med (2008) 2.11
Leptin resistance contributes to obesity and hypertension in mouse models of Bardet-Biedl syndrome. J Clin Invest (2008) 2.07
Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension (2003) 2.06
Assessment of drug-induced increases in blood pressure during drug development: report from the Cardiac Safety Research Consortium. Am Heart J (2013) 2.05
Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. JAMA (2003) 2.04
When the time comes to talk about HIV: factors associated with diagnostic disclosure and emotional distress in HIV-infected children. J Acquir Immune Defic Syndr (2002) 2.01
ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation (2011) 1.97
Blood pressure measurement reliability among different racial-ethnic groups in a stroke prevention study. Blood Press Monit (2014) 1.97
Profiling patterned transcripts in Drosophila embryos. Genome Res (2002) 1.96
Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J (2012) 1.95
Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis (2011) 1.88
Predictors of HIV-related stigma among young people living with HIV. Health Psychol (2006) 1.81
The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med (2005) 1.76
Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension (2010) 1.74
Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med (2002) 1.73
Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst (2010) 1.73
The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension (2006) 1.71
Position statement executive summary: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care (2011) 1.71
Alternative endpoints for mortality in studies of patients with atrial fibrillation: the AFFIRM study experience. Heart Rhythm (2004) 1.70
Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension (2011) 1.69
G-protein-coupled receptor kinase 4 polymorphisms and blood pressure response to metoprolol among African Americans: sex-specificity and interactions. Am J Hypertens (2009) 1.66
The OSCAR for cardiovascular disease prevention in chronic kidney disease goes to blood pressure control. Kidney Int (2013) 1.65
Body weight changes with beta-blocker use: results from GEMINI. Am J Med (2007) 1.60
Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens (2004) 1.60
Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial. J Hypertens (2007) 1.59
Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial. JAMA (2013) 1.54
Tree-structured gatekeeping tests in clinical trials with hierarchically ordered multiple objectives. Stat Med (2007) 1.54
Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Press (2007) 1.52
Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis (2009) 1.52
Effects of hospital closures and hospital characteristics on emergency department ambulance diversion, Los Angeles County, 1998 to 2004. Ann Emerg Med (2006) 1.52
Combination therapy in hypertension. J Am Soc Hypertens (2010) 1.51
Renal outcomes in hypertensive Black patients at high cardiovascular risk. Kidney Int (2011) 1.51
Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies. Circ Heart Fail (2010) 1.50
Altered expression of endothelin receptors in failing human left ventricles. J Mol Cell Cardiol (2002) 1.50
Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. Blood Press (2005) 1.49
Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy. Am J Geriatr Cardiol (2008) 1.48
Care of undocumented individuals with ESRD: a national survey of US nephrologists. Am J Kidney Dis (2009) 1.48
Effect of combining extended-release carvedilol and lisinopril in hypertension: results of the COSMOS study. J Clin Hypertens (Greenwich) (2010) 1.46
Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood institute. Hypertension (2008) 1.46
Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. Am Heart J (2008) 1.46
Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich) (2011) 1.44